Information  X 
Enter a valid email address

Arix Bioscience PLC 0.001P (ARIX)

Related News

02-Oct-2019 09:16 AM

Arix Bioscience CEO James Rawlingson departs; Marcus Karia promoted to group finance director

Venture capital company Arix Bioscience said CEO James Rawlingson had left the company and group financial controller, Marcus Karia was promoted group finance director. At 9:16am: (LON:ARIX) Arix Bioscience Plc share price was 0p at 111.5p Story prov
28-Aug-2019 09:48 AM

Arix Bioscience swings to loss, blames slump in shares of Autolus

Venture capital company Arix Bioscience swung to a half-yearly loss as net asset value per share fell 14.5% thanks to a slump in Autolus' share price. For the period ended 30 June 2019, the company reported a pre-tax loss of £44.8m, compared
24-Oct-2018 10:28 AM

Arix Bioscience stake in LogicBio Therapeutics delivers bumper gains following IPO

Healthcare company Arix Bioscience said Wednesday its 12.9% stake in LogicBio Therapeutics, one of its group businesses, was valued at £22.9m after the latter closed its initial public offering. LogicBio Therapeutics closed its initial public offe
18-Jul-2018 08:10 AM

Broker Forecast - Jefferies International issues a broker note on Arix Bioscience Plc

Jefferies International today reaffirms its buy investment rating on Arix Bioscience Plc (LON:ARIX) and raised its price target to 275p (from 268p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
23-Apr-2018 02:24 PM

Arix Bioscience losses narrow, expands portfolio to 13 companies

Arix Bioscience, which listed on the London Stock Exchange in February 2017, said annual losses narrowed, as it upped its investment portfolio to holdings in 13 life sciences companies from eight. Pre-tax losses amounted to £7.7m, compared to &poun
19-Feb-2018 09:07 AM

Arix, Fosun agree partnership to develop, commercialise new clinical therapies

Arix Bioscience and Fosun jointly announced a strategic agreement to develop and commercialise new clinical therapies for patients with a particular emphasis on the Chinese market. Arix will provide Fosun with access to its group businesses, pipeline and
04-Jan-2018 02:15 PM

Arix outlines 2017 achievements and 2018 objectives

In a letter from the CEO to shareholders, Arix Bioscience has confirmed that during 2017 the Company has directed a substantive amount capital into 13 promising young life science companies. To date, the Company has committed around $105m into these comp
21-Dec-2017 09:40 AM

Arix Bioscience co-leads $30m financing for Aura Biosciences

Arix Bioscience has co-led a $30 million series C financing round for Aura Biosciences. Aura is developing a new class of therapies to selectively destroy cancer cells. Its lead candidate is targeting ocular melanoma, a rare and aggressive eye cancer
10-Nov-2017 09:11 AM

Arix Bioscience non-exec to step down

Arix Bioscience non-executive director Sir John Banham is retiring from the board. The company said: 'Sir John, who is 76, has been chairman of the audit and risk committee, and has helped to oversee the company's growth both as a private comp
17-Oct-2017 09:18 AM

Arix Bioscience strengthens its board

Arix Bioscience has appointed Giles Kerr as a non-executive director and chairman of the board's audit committee. Kerr has 36 years' experience in finance across a broad range of industrial sectors with a particular focus on life sciences.
10-Oct-2017 08:01 AM

Arix Bioscience notes positive data from Amplyx

Arix Bioscience has notes the release of positive clinical and non-clinical data by Amplyx Pharmaceuticals, an Arix Bioscience Group Business, at IDWeek 2017, held in San Diego. The data showed that Amplyx's lead candidate APX001, a novel, broad-spe
18-Sep-2017 08:24 AM

Arix Bioscience notes positive progress by Autolus

Arix Bioscience has noted two positive press releases today by Autolus, an Arix Bioscience Group business, announcing clinical progress across its portfolio. It said the first release from Autolus announced the completion of the first-dose cohort of its
11-Sep-2017 08:44 AM

Arix to present at Rodman & Renshaw conference

Arix Bioscience will present at the 19th annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference is being held at the Lotte New York Palace Hotel in New York City and the Arix Bioscience presentation is t
07-Sep-2017 02:18 PM

Arix notes positive trial data from Verona Pharma for RPL554

Arix Bioscience said it has noted the announcement made by Verona Pharma, one of its Group businesses, of positive top-line results from its Phase 2a clinical trial for RPL554 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD
02-Aug-2017 07:44 AM

Arix participates in $67m financing for Amplyx

Arix Bioscience has acquired an interest in Amplyx Pharmaceuticals as part of an oversubscribed $67 million series C financing round. San Diego-based Amplyx is focused on developing novel, broad-spectrum antifungal agents for the treatment of life-threa
31-Jul-2017 08:00 AM

Arix Bioscience losses widen

Arix Bioscience posts a pre-tax loss of £6.7m for the six months to the end of June compared with £2.8m fro the period from 15 September 2015 to the end of June 2016. Revenues rose to £574,000 from £5,000 while administrative expe
10-Jul-2017 08:16 AM

Arix Bioscience appoints general counsel

Arix Bioscience - a global healthcare and life science company supporting medical innovation - has appointed Robert Lyne as its general counsel. Arix Bioscience said that Lyne would support the strategic and operational direction of the company. The
28-Jun-2017 08:06 AM

Arix Bioscience leads LogicBio financing round

Arix Bioscience has led an oversubscribed series B financing round raising $45m for LogicBio Therapeutics, a new Arix Group business focused on breakthrough, disease-modifying gene therapies for orphan paediatric diseases. The fundraising included new i
27-Jun-2017 01:02 PM

Arix acquires interest in Mitoconix Bio

Arix Bioscience has announced that it has acquired an interest in Mitoconix Bio as part of its oversubscribed $20m Series A financing round. At 1:02pm: (LON:ARIX) Arix Bioscience Plc share price was 0p at 205.5p Story provided by StockMarketWire.co
12-Jun-2017 08:38 AM

Arix notes Artios collaboration

Arix Bioscience has noted an announcement by Artios Pharma, an Arix Bioscience Group Business, that it has signed a research collaboration and option agreement with Masaryk University in the Czech Republic for the development of novel cancer treatments ta
25-May-2017 09:09 AM

Arix Bioscience co-leads Harpoon Therapeutics financing

Arix Bioscience has announced that Harpoon Therapeutics, a new Arix Group business, has closed a series B investment round raising $45 million. Arix Bioscience co-led the financing round with New Leaf Venture Partners, and additional new investor Taiho
15-May-2017 09:40 AM

Broker Forecast - Jefferies International issues a broker note on Arix Bioscience Plc

Jefferies International today initiates coverage of Arix Bioscience Plc (LON:ARIX) with a buy investment rating and price target of 245p. Story provided by StockMarketWire.com...
18-Apr-2017 02:36 PM

Arix notes VRP's announcement over RPL554 trial in US

Arix Bioscience said it has noted the announcement made by Verona Pharma, in which it has a 6.6% holding, that it has received authorisation from the Food and Drug Administration to proceed with the first clinical trial of RPL554 in the US. Arix added:
02-Mar-2017 07:58 AM

Arix Bioscience inks strategic agreement with Takeda

Arix Bioscience, a global healthcare and life science company supporting medical innovation, has signed a strategic agreement with Takeda Ventures. The agreement will maximise the complementary skills and experience of both Arix and Takeda across import
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t